CAMBRIDGE, Mass., March 03, 2021 (World NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical corporation centered on identifying, building and commercializing therapies
Tag: Therapeutics
Gyroscope Therapeutics Appoints Jessica Stitt as Chief Monetary Officer | Company & Finance
LONDON–(Company WIRE)–Mar 1, 2021– Gyroscope Therapeutics Constrained, a medical-phase gene treatment enterprise targeted on diseases of the eye, nowadays introduced the appointment of Jessica Stitt
Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
– UPLIFT, a single-arm registration strategy evaluating upifitamab rilsodotin (UpRi) in platinum-resistant ovarian cancer, on track to begin in Q1 2021 – Significantly progressed pipeline
Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates
Karuna Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides General Business Update
Two Phase 3 trials, EMERGENT-2 and EMERGENT-4, initiated evaluating KarXT for the treatment of psychosis in adults with schizophrenia Results from the Phase 2 EMERGENT-1
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full
Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
– Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 – – Completed sixth dosing
Antios Therapeutics Appoints Attained Money Executive, Tamra J. Adams, as its initially Main Financial Officer
TipRanks 2 “Strong Buy” Dividend Stocks Yielding at Minimum 7% A selection of variables are coming with each other in the marketplace photo, and point
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
– More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in
Gemini Therapeutics Appoints Brian Piekos as Chief Financial Officer | Business & Finance
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb 9, 2021– Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration